Literature DB >> 17922087

High-dose bisphosphonate therapy in an urgent case of spontaneous multiple vertebral fractures in a 55 year old woman.

Christian Muschitz1, Paul Roschger, Janina Patsch, Isabella Pollhammer, Bruno Koller, Klaus Klaushofer, Heinrich Resch.   

Abstract

An early postmenopausal Caucasian woman aged 55 sustained multiple vertebral fractures after a minor trauma. After exclusion of any kind of secondary osteoporosis, we administered due to clinical severity combined oral and cyclic intravenous bisphosphonate therapy (oral risedronate 35 mg/week, i.v. pamidronate 30 mg quarterly) with adequate calcium and vitamin D supplementation for 28 months. We performed a transiliac bone biopsy at baseline and at month 28. The paired samples were investigated by histomorphometry, by microCT-analysis for 3d structure and by qBEI representing bone mineral density distribution. Mineralisation of the bone matrix was not influenced by supplementation of calcium and vitamin D. Parameters of bone architecture and BMD improved; and a reduction of pain and increased mobility was observed. No further osteoporotic fractures occurred during the time of investigation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17922087     DOI: 10.1007/s10354-007-0445-3

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  11 in total

1.  Effects of 3- and 5-year treatment with risedronate on bone mineralization density distribution in triple biopsies of the iliac crest in postmenopausal women.

Authors:  Ruth Zoehrer; Paul Roschger; Eleftherios P Paschalis; Jochen G Hofstaetter; Erich Durchschlag; Peter Fratzl; Roger Phipps; Klaus Klaushofer
Journal:  J Bone Miner Res       Date:  2006-07       Impact factor: 6.741

2.  Vertebral morphometry in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate treatment.

Authors:  Christof Land; Frank Rauch; Craig F Munns; Solmaz Sahebjam; Francis H Glorieux
Journal:  Bone       Date:  2006-05-26       Impact factor: 4.398

3.  Analgesic effect of intravenous pamidronate on chronic back pain due to osteoporotic vertebral fractures.

Authors:  V Gangji; T Appelboom
Journal:  Clin Rheumatol       Date:  1999       Impact factor: 2.980

Review 4.  Optimizing administration of bisphosphonates in women with postmenopausal osteoporosis.

Authors:  Paula J Rackoff; Anthony Sebba
Journal:  Treat Endocrinol       Date:  2005

5.  Assessment of vitamin D and calcium status in healthy adult Austrians.

Authors:  S Kudlacek; B Schneider; M Peterlik; G Leb; K Klaushofer; K Weber; W Woloszczuk; R Willvonseder
Journal:  Eur J Clin Invest       Date:  2003-04       Impact factor: 4.686

6.  Constant mineralization density distribution in cancellous human bone.

Authors:  P Roschger; H S Gupta; A Berzlanovich; G Ittner; D W Dempster; P Fratzl; F Cosman; M Parisien; R Lindsay; J W Nieves; K Klaushofer
Journal:  Bone       Date:  2003-03       Impact factor: 4.398

7.  The effect of risedronate on bone mineralization as measured by micro-computed tomography with synchrotron radiation: correlation to histomorphometric indices of turnover.

Authors:  Babul Borah; Erik L Ritman; Thomas E Dufresne; Steven M Jorgensen; Sheng Liu; Jarek Sacha; Roger J Phipps; Russell T Turner
Journal:  Bone       Date:  2005-07       Impact factor: 4.398

8.  Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture.

Authors:  J A Kanis; I P Barton; O Johnell
Journal:  Osteoporos Int       Date:  2004-07-23       Impact factor: 4.507

9.  Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography.

Authors:  T E Dufresne; P A Chmielewski; M D Manhart; T D Johnson; B Borah
Journal:  Calcif Tissue Int       Date:  2003-09-11       Impact factor: 4.333

10.  Bisphosphonate treatment affects trabecular bone apparent modulus through micro-architecture rather than matrix properties.

Authors:  J S Day; M Ding; P Bednarz; J C van der Linden; T Mashiba; T Hirano; C C Johnston; D B Burr; I Hvid; D R Sumner; H Weinans
Journal:  J Orthop Res       Date:  2004-05       Impact factor: 3.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.